leadf
logo-loader
viewBioSig Technologies, Inc.

BioSig Technologies enrolling patients in its Phase 2 clinical trial to treat coronavirus in major US hotspots

BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner tells Proactive the Connecticut-based biotech is enrolling patients for its Phase 2 trial of merimepodib, its drug candidate for the treatment of the coronavirus.

Londoner says BioSig, along with its subsidiary ViralClear Pharmaceuticals Inc, is enrolling patients at trial sites in Austin, Texas; Rochester, Minnesota; Jacksonville, Florida; and Scottsdale, Arizona, expecting to report results later this summer.

Quick facts: BioSig Technologies, Inc.

Price: 3.41 USD

NASDAQ:BSGM
Market: NASDAQ
Market Cap: $101.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioSig Technologies, Inc. named herein, including the promotion by the Company of BioSig Technologies, Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

BioSig teams up with Sorrento Therapeutics to fight the coronavirus with a...

BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner tells Proactive the group's subsidiary ViralClear Pharmaceuticals, Inc is teaming up with Sorrento Therapeutics, Inc. (NASDAQ: SRNE) to advance the fight against the coronavirus. Londoner says the two biotechs will look at the effective...

4 weeks, 1 day ago

2 min read